Literature DB >> 32568554

Development of a Data Model and Data Commons for Germ Cell Tumors.

Bo Ci1, Donghan M Yang1, Mark Krailo2,3, Caihong Xia3, Bo Yao1, Danni Luo1, Qinbo Zhou1, Guanghua Xiao1,4, Lin Xu1, Stephen X Skapek5,6, Matthew M Murray7, James F Amatruda2,8, Lindsay Klosterkemper9, Furqan Shaikh10, Cecile Faure-Conter11, Brice Fresneau12, Samuel L Volchenboum13, Sara Stoneham14, Luiz Fernando Lopes15, James Nicholson16, A Lindsay Frazier9, Yang Xie1,4,6.   

Abstract

Germ cell tumors (GCTs) are considered a rare disease but are the most common solid tumors in adolescents and young adults, accounting for 15% of all malignancies in this age group. The rarity of GCTs in some groups, particularly children, has impeded progress in treatment and biologic understanding. The most effective GCT research will result from the interrogation of data sets from historical and prospective trials across institutions. However, inconsistent use of terminology among groups, different sample-labeling rules, and lack of data standards have hampered researchers' efforts in data sharing and across-study validation. To overcome the low interoperability of data and facilitate future clinical trials, we worked with the Malignant Germ Cell International Consortium (MaGIC) and developed a GCT clinical data model as a uniform standard to curate and harmonize GCT data sets. This data model will also be the standard for prospective data collection in future trials. Using the GCT data model, we developed a GCT data commons with data sets from both MaGIC and public domains as an integrated research platform. The commons supports functions, such as data query, management, sharing, visualization, and analysis of the harmonized data, as well as patient cohort discovery. This GCT data commons will facilitate future collaborative research to advance the biologic understanding and treatment of GCTs. Moreover, the framework of the GCT data model and data commons will provide insights for other rare disease research communities into developing similar collaborative research platforms.

Entities:  

Year:  2020        PMID: 32568554      PMCID: PMC7328105          DOI: 10.1200/CCI.20.00025

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  16 in total

Review 1.  Second malignant neoplasms and cardiovascular disease following radiotherapy.

Authors:  Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice
Journal:  J Natl Cancer Inst       Date:  2012-02-06       Impact factor: 13.506

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Web services for data warehouses: OMOP and PCORnet on i2b2.

Authors:  Jeffrey G Klann; Lori C Phillips; Christopher Herrick; Matthew A H Joss; Kavishwar B Wagholikar; Shawn N Murphy
Journal:  J Am Med Inform Assoc       Date:  2018-10-01       Impact factor: 4.497

Review 4.  Chemotherapeutic and surgical strategies for germ cell tumors.

Authors:  Lawrence H Einhorn
Journal:  Chest Surg Clin N Am       Date:  2002-11

5.  Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

Authors:  Aditya Bagrodia; Byron H Lee; William Lee; Eugene K Cha; John P Sfakianos; Gopa Iyer; Eugene J Pietzak; Sizhi Paul Gao; Emily C Zabor; Irina Ostrovnaya; Samuel D Kaffenberger; Aijazuddin Syed; Maria E Arcila; Raju S Chaganti; Ritika Kundra; Jana Eng; Joseph Hreiki; Vladimir Vacic; Kanika Arora; Dayna M Oschwald; Michael F Berger; Dean F Bajorin; Manjit S Bains; Nikolaus Schultz; Victor E Reuter; Joel Sheinfeld; George J Bosl; Hikmat A Al-Ahmadie; David B Solit; Darren R Feldman
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

Review 6.  Testicular germ-cell tumours in a broader perspective.

Authors:  J Wolter Oosterhuis; Leendert H J Looijenga
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

7.  Cardiovascular disease as a long-term complication of treatment for testicular cancer.

Authors:  R A Huddart; A Norman; M Shahidi; A Horwich; D Coward; J Nicholls; D P Dearnaley
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

8.  Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.

Authors:  Barbara Cushing; Roger Giller; John W Cullen; Neyssa M Marina; Stephen J Lauer; Thomas A Olson; Paul C Rogers; Paul Colombani; Frederick Rescorla; Deborah F Billmire; Charles D Vinocur; Edith P Hawkins; Mary Margaret Davis; Elizabeth J Perlman; Wendy B London; Robert P Castleberry
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

9.  Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study.

Authors:  B Fresneau; D Orbach; C Faure-Conter; H Sudour-Bonnange; C Vérité; V Gandemer; M Pasquet; S Fasola; A Rome; S Raimbault; H Martelli; D Frappaz; G Le Teuff; C Patte
Journal:  Eur J Cancer       Date:  2018-03-28       Impact factor: 9.162

10.  Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91.

Authors:  Luiz Fernando Lopes; Carla Renata Pacheco Macedo; Elitânia Marinho Pontes; Simone Dos Santos Aguiar; Maria José Mastellaro; Renato Melaragno; Sonia Maria Rossi Vianna; Paula Azevedo Allemand Lopes; Nubia Mendonça; Maria Teresa de Assis Almeida; Viviane Sonaglio; Karina B Ribeiro; Victor M Santana; Dominik T Schneider; Beatriz de Camargo
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

View more
  1 in total

Review 1.  Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium.

Authors:  Adriana Fonseca; João Lobo; Florette K Hazard; Joanna Gell; Peter K Nicholls; Robert S Weiss; Lindsay Klosterkemper; Samuel L Volchenboum; James C Nicholson; A Lindsay Frazier; James F Amatruda; Aditya Bagrodia; Michelle Lockley; Matthew J Murray
Journal:  Br J Cancer       Date:  2022-10-13       Impact factor: 9.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.